Bleomycin A6

DRACPC ID  DRACPC0051

Active Ingredients   Bleomycin A6

Description  A component of the antibiotic bleomycin produced by Streptomyces species, with potential antineoplastic activity. Upon administration, boanmycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals. This causes single- and double-stranded DNA breaks which eventually leads to cell death. Compared to bleomycin, boanmycin appears to have a more favorable toxicity profile.

Synonyms  Bleomycin; Bleomycin A6

Type  Small Molecule

Disease  Squamous Cell Lung Cancer

Classification

  

Peptide and derivative

Structure Information


Molecular Formula  C60H96N20O21S2

Molecular Weight  1497.7

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-5-[[(2S,3R)-1-[2-[4-[4-[3-[4-(3-aminopropylamino)butylamino]propylcarbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]ethylamino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-4-methyl-5-oxopentan-2-yl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate

InChI  InChI=1S/C60H96N20O21S2/c1-25-38(77-51(80-49(25)64)30(17-36(63)84)72-18-29(62)50(65)90)55(94)79-40(46(31-19-69-24-73-31)99-59-48(44(88)42(86)34(20-81)98-59)100-58-45(89)47(101-60(66)96)43(87)35(21-82)97-58)56(95)74-27(3)41(85)26(2)52(91)78-39(28(4)83)54(93)71-16-9-37-75-33(23-102-37)57-76-32(22-103-57)53(92)70-15-8-14-68-12-6-5-11-67-13-7-10-61/h19,22-24,26-30,34-35,39-48,58-59,67-68,72,81-83,85-89H,5-18,20-21,61-62H2,1-4H3,(H2,63,84)(H2,65,90)(H2,66,96)(H,69,73)(H,70,92)(H,71,93)(H,74,95)(H,78,91)(H,79,94)(H2,64,77,80)/t26-,27+,28+,29-,30-,34-,35+,39-,40-,41-,42+,43+,44-,45-,46-,47-,48-,58+,59-/m0/s1

InChI_Key FOUFFVYWFNBHHH-YNGSZULRSA-N

SMILES  CC1=C(N=C(N=C1C(N[C@@H]([C@H](C2=CN=CN2)O[C@@H]3O[C@H]([C@H]([C@@H]([C@@H]3O[C@H]4O[C@@H]([C@H]([C@@H]([C@@H]4O)OC(N)=O)O)CO)O)O)CO)C(N[C@@H]([C@H]([C@@H](C(N[C@@H]([C@H](O)C)C(NCCC5=NC(C6=NC(C(NCCCNCCCCNCCCN)=O)=CS6)=CS5)=O)=O)C)O)C)=O)=O)[C@@H](NC[C@@H](C(N)=O)N)CC(N)=O)N

External Codes


PubChem CID  9877229

DrugBank Accession Number  DB12992

NCI Thesaurus Code  C102878  

UNII  0B19OCB220   GSRS

CAS  37293-17-7



Drug approval


Drug indication
    Bleomycin A6 participated in clinical trials for the treatment of Squamous Cell Lung Cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT01660399 Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial Squamous Cell Lung Cancer Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.